Serum antibodies to defined carbohydrate antigens during the course of treated leprosy.
Sequential monitoring of 724 sera for antibodies to a neoantigen based on phenolic glycolipid-I (PGL-I) and native lipoarabinomannan (LAM) in 90 leprosy patients undergoing therapy in San Francisco was conducted. Untreated lepromatous patients frequently (91%) had significant antibodies to both moieties. Antibodies were less frequently found in tuberculoid patients (74% to neoantigen and 37% to LAM). In the first 3 years of treatment, average serum antibodies to both moieties fell significantly. Antibodies to LAM fell during each of the first 4 years of therapy, but decreasing antibody levels to the PGL-I neoantigen did not appear to fall consistently after the third year of treatment. A wide variation in the rate of fall of serum antibodies was noted. Sequential changes in the amounts of serum antibodies to the neoantigen and LAM in general paralleled one another but were at times discrepant. Both in San Francisco and Malaysia, skin-smear negative, long-term treated, lepromatous leprosy patients frequently harbored significant antibodies to both PGL-I and LAM.
Gelber
R H
RH
Kuzell Institute, San Francisco, California 94115.
Li
F
F
Cho
S N
SN
Byrd
S
S
Rajagopalan
K
K
Brennan
P J
PJ
D000907:Antibodies, Bacterial / Q000032:analysis*; D000942:Antigens, Bacterial / Q000276:immunology*; D006017:Glycolipids / Q000276:immunology*; D006801:Humans; D007918:Leprosy / Q000276:immunology* / Q000628:therapy; D008070:Lipopolysaccharides / Q000276:immunology*; D009166:Mycobacterium leprae / Q000276:immunology*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D006017:Glycolipids; D008070:Lipopolysaccharides; C050016:lipoarabinomannan; C045169:phenolic glycolipid I, Mycobacterium leprae